Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOUCHET, Julie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
IDREF: 221043470
dc.contributor.authorRASCHI, E.
dc.contributor.authorPOLUZZI, E.
dc.contributor.authorANTONAZZO, I. C.
dc.contributor.authorDE PONTI, F.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
dc.date.accessioned2020-12-08T14:09:42Z
dc.date.available2020-12-08T14:09:42Z
dc.date.issued2018-03-14
dc.identifier.issn1873-2518 (Electronic) 0264-410X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/21364
dc.description.abstractEnBACKGROUND: The anti-hepatitis B immunization campaigns launched in the early 1990s were a major public health breakthrough and targeted various populations (at-risk adults, newborns, adolescents). However, debate is still active about a possible link between this vaccine and central demyelination. This study provides a pooled estimate of this risk based on a comprehensive review and meta-analysis of all available epidemiologic studies. METHODS: A systematic review was conducted in Medline, Embase, ISI Web of Science and the Cochrane Library from database inception to 10 May 2017. Grey literature was searched and snowballing was also undertaken. Only observational studies including a control group were retained. Primary outcome was multiple sclerosis diagnosed by recognized criteria. Study selection was performed by two independent reviewers with disagreements solved through discussion. This meta-analysis based on crude, adjusted estimates, or risks limited to the 3months following immunization was performed using a generic inverse variance random-effect model. Heterogeneity was investigated; sensitivity and subgroup analyses were performed when necessary. This study followed the PRISMA statement and the MOOSE reporting guideline (Study protocol registered in PROSPERO: CRD42015020808). FINDINGS: Of the 2804 references reviewed, 13 studies with a control group were analysed. None of the pooled risk estimates for either multiple sclerosis or central demyelination following HB immunization reached statistical significance. When considering adjusted risk ratios, the following non-significant figures were obtained: 1.19 (95%CI: 0.93 - 1.52) and 1.25 (95%CI: 0.97 - 1.62), for multiple sclerosis and central demyelination, respectively. CONCLUSIONS: No evidence of an association between hepatitis B vaccination and central demyelination was found.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enHepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis
dc.title.alternativeVaccineen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.vaccine.2018.02.036en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29454521en_US
bordeaux.journalVaccineen_US
bordeaux.page1548-1555en_US
bordeaux.volume36en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue12en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03194147
hal.version1
hal.date.transferred2021-04-09T11:10:08Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Vaccine&rft.date=2018-03-14&rft.volume=36&rft.issue=12&rft.spage=1548-1555&rft.epage=1548-1555&rft.eissn=1873-2518%20(Electronic)%200264-410X%20(Linking)&rft.issn=1873-2518%20(Electronic)%200264-410X%20(Linking)&rft.au=MOUCHET,%20Julie&SALVO,%20Francesco&RASCHI,%20E.&POLUZZI,%20E.&ANTONAZZO,%20I.%20C.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée